
Experts weigh in on standout breast cancer, lung cancer, melanoma, and kidney cancer data presented at the 2026 ESMO Congress.
Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the KEYNOTE-564 trial in renal cell carcinoma.
Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the KEYNOTE-564 trial in renal cell carcinoma (RCC).
KEYNOTE-564 is an ongoing trial that is randomizing patients to pembrolizumab (Keytruda) or placebo, with a primary endpoint of disease-free survival.
This trial is enrolling high-risk patients with RCC, says Zhang, but it will also enroll patients with metastatic disease and have had metastasectomies—which is a unique feature of KEYNOTE-564.



